Johnson and johnson (NYSE: JNJ) Coronavirus has gained some ground in the vaccine race. On Thursday, the Pharmaceutical and Consumer Goods Company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate with SARS-CoV-2 had demonstrated effectiveness in protecting non-human primates from infection. .
Unlike other coronavirus vaccine candidates – as many observers see as the most promising, ModernamRNA-1273 – Johnson & Johnson responded with a single dose.
Based on those results, Johnson & Johnson has begun testing its candidate on humans in phase 1 / 2a clinical trials in the US and Belgium. For those studies, Ad26.COV2-S will be administered in single- and double-dose regimens; The company will use the tests to assess its safety, immunogenicity (ability to produce immune responses), and its ability to cause adverse reactions.
More than 1,000 healthy adults between the ages of 18 and 55, as well as those 65 and older, will participate in the trial. The company also plans to conduct a Phase 2A trial in the Netherlands, Spain and Germany and a Phase 1 study in Japan.
Johnson & Johnson aims to advance Ad26.COV2-S through the clinical study process with some haste. Chief Scientific Officer Paul Stoffels said, “As per the findings we are confident of intending to start the Phase 1/2 A trial in July, furthering our vaccine development and upscale manufacturing in parallel.”
Major pharmaceutical companies, as well as a fleet of several biotechs, are developing vaccine candidates, drugs, or both to counter COVID-19. But while some drugs have shown some promise as a treatment for novel coronaviruses, no vaccine candidate for it has yet demonstrated its effectiveness in Phase 3 trials – before the decisive step wins regulatory approval and To market. public.
On Thursday, Johnson & Johnson shares boosted the market’s bearish trend – albeit only 2%.